Welcome to our dedicated page for Eledon Pharmaceuticals news (Ticker: ELDN), a resource for investors and traders seeking the latest updates and insights on Eledon Pharmaceuticals stock.
Eledon Pharmaceuticals develops immune-modulating therapies as a clinical-stage biotechnology company focused on transplant medicine and other life-threatening conditions. Its lead investigational product, tegoprubart, is an anti-CD40L antibody designed to target the CD40 Ligand pathway, with programs and study updates tied to kidney allograft transplantation, xenotransplantation, islet cell transplantation, liver transplantation and amyotrophic lateral sclerosis.
Company news commonly covers tegoprubart clinical data, investigator-initiated transplant studies, FDA orphan drug designations, research collaborations, conference presentations and operating results. Updates also address how the company positions CD40L modulation as a non-lymphocyte-depleting immunomodulatory approach for preventing organ rejection and supporting transplanted cell or organ grafts.
Eledon Pharmaceuticals (NASDAQ: ELDN) announces its participation in two significant medical conferences this November. At the American Society of Nephrology's Kidney Week 2022 (November 3-6 in Orlando, FL), Eledon will present two posters focusing on the safety and efficacy of tegoprubart in treating IgA nephropathy and its potential for ALS. Additionally, a poster on tegoprubart's safety profile in ALS will be showcased at the Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) conference (November 1-3 in Clearwater Beach, FL). Eledon specializes in treatments for autoimmune diseases and organ transplant needs.
Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) announced participation in two upcoming conferences. On October 6, Steven Perrin, Ph.D., will engage in a panel discussion on ALS treatment at the Cantor Neurology & Psychiatry Conference. On October 7, Jeff Bornstein, M.D., will present on the safety and efficacy of tegoprubart for ALS patients at the ALS One 5th Annual ALS Research Symposium. Both presentations are exclusive to registered attendees. Eledon focuses on developing therapies targeting the CD40L pathway for organ transplant, autoimmune diseases, and ALS.
Eledon Pharmaceuticals (NASDAQ: ELDN) announced that CEO David-Alexandre C. Gros will participate in a fireside chat at the Ladenburg Thalmann Healthcare Conference on September 29, 2022, at 2:00 p.m. ET in New York City. Interested parties can register for the webcast here. A replay will be available afterward on the company’s website.
Eledon specializes in developing treatments targeting the CD40 Ligand pathway for transplant patients and those with autoimmune diseases.
Eledon Pharmaceuticals has announced FDA clearance of its IND application for tegoprubart, aimed at treating IgA Nephropathy (IgAN). The Phase 2a clinical trial, now active in 10 countries including the U.S., will evaluate safety and efficacy in patients with severe proteinuria. The study's primary endpoint focuses on changes in urine protein levels after 24 weeks. Currently, IgAN affects around 150,000 Americans, underscoring the urgency for effective treatments amid limitations of standard therapies.
Eledon Pharmaceuticals, listed on NASDAQ as ELDN, announced its participation in two investor conferences. The first event is a fireside chat at the Gilmartin Group Emerging Growth Company Showcase on August 31, 2022, at 2:00 p.m. ET. The second event is a presentation at the H.C. Wainwright 24th Annual Global Investment Conference, available on-demand from September 12, 2022, at 7:00 a.m. ET. Webcast replays will be accessible on the company's website. Eledon focuses on developing treatments targeting the CD40 Ligand pathway, with its lead candidate being tegoprubart.
Eledon Pharmaceuticals (NASDAQ: ELDN) received FDA clearance for a Phase 2 trial of tegoprubart, aimed at preventing organ rejection in kidney transplant patients. The company has initiated a Phase 1b trial with the first patient dosed in Canada, the UK, and Australia. Positive topline results were reported from a Phase 2a trial of tegoprubart in ALS, showing safety, target engagement, and biomarker response. The drug also received Orphan Drug Designation for pancreatic islet cell transplantation. Eledon plans to provide further data in Q1 2023.
Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) plans to release its financial results for Q2 2022 on August 11, after market close. Management will host a conference call and webcast at 4:30 pm ET to discuss these results. Eledon specializes in developing treatments for organ transplantation, autoimmune diseases, and neurodegenerative disorders, focusing on its lead compound, tegoprubart. This anti-CD40L antibody targets a key biological pathway, promising significant therapeutic potential.
Eledon Pharmaceuticals (NASDAQ: ELDN) announced that the FDA has approved its Investigational New Drug (IND) application for tegoprubart to prevent kidney transplant rejection.
The phase 2 study will enroll around 120 participants, comparing tegoprubart to tacrolimus over 12 months. The main goal is to evaluate graft function via eGFR. Tegoprubart aims to improve graft survival and reduce side effects associated with current therapies.
Eledon Pharmaceuticals (NASDAQ: ELDN) has announced the dosing of the first patient in a Phase 1b study of tegoprubart for kidney transplantation. This open-label trial, authorized in Canada and the UK, aims to enroll 12 patients receiving tegoprubart along with standard induction therapy. It will assess safety, pharmacokinetics, and efficacy, including rates of acute rejection. The study addresses the challenges posed by existing immunosuppressive therapies associated with significant side effects. Eledon sees tegoprubart as a potential game-changer in managing kidney transplants.
Eledon Pharmaceuticals (NASDAQ: ELDN) announced the grant of inducement stock options to new employees covering 180,000 shares at an exercise price of $3.06, closing price on June 6, 2022. These options have a 10-year term and will vest over four years, with 25% vesting after one year. Eledon focuses on developing treatments for organ and cell transplantation, autoimmune diseases, and neurodegenerative disorders, primarily through its lead compound, tegoprubart, an anti-CD40L antibody targeting key therapeutic pathways.